Primary Medical Treatment of Thyrotropin–Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients

Abstract

This study confirms the efficacy of primary medical treatment with first-generation somatostatin analogs in terms of hormonal control and tumor volume reduction in patients with TSH-secreting pituitary adenomas, and its good safety profile. First-generation somatostatin analogs may serve as a medical alternative to surgical treatment, especially in patients where surgery is contraindicated or in subjects presenting with invasive macroadenomas that render complete surgical resection difficult.